Abstract
performed. Non-responder imputation was used for missing data or that obtained after move to weekly dosing. Results: Mean BL CDAI, CDEIS, and SES-CD scores were 253.9, 8.9, and 11.0, for pts with moderately active CD, and 365.9, 11.4, and 13.6, for pts with severely active CD, respectively. A greater proportion of ADA-treated than induction ADA only/PBO-treated pts achieved MH at week 12 in both severity subgroups, although the differences were not statistically significant (Table, ADA vs PBO, p = 0.1 moderate CD, p = 0.3 severe CD). Statistically significant differences in MH rates were observed at week 12 in anti-TNF naive pts with moderate CD treated with ADA compared to induction ADA only/PBO-treated pts (37.5% vs 0, p < 0.05). Significantly more ADA-treated pts than induction ADA only/PBO pts had mucosal healing at week 52 in both severity groups (Table). None of the induction ADA only/PBO-treated pts had MH at week 52. Previous anti-TNF exposure did not show a consistent influence on MH outcomes.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
